
41st anniversary of The Times of India, Bengaluru: Troika of science, culture, experiment
Tired of too many ads? go ad free now
The gallery is part of an international network of galleries in London, Melbourne, and Monterrey – and it's Asia's first, India's only, and the world's largest such gallery. It's the only freestanding gallery in the network not based on a university campus. Established with founding support from the Karnataka govt with close relationships with Indian Institute of Science and National Centre for Biological Sciences, the Gallery is built through public-private partnership.
We do three things at the Gallery: public engagement, public labs, and civic spaces. The public engagement complex has exhibition halls, an open studio, and lecture rooms which we have in common with other galleries in the Science Gallery Network. Unique to Bengaluru is the Public Lab Complex with its five experimental spaces: a nature lab, a materials lab, a food lab, a new media lab and a theory lab. In addition, we have civic spaces like the reading room, a patio, a portico and an outdoor café, where young adults are invited pursue their own activities together.
If people want to meet regularly to try out natural dyes or build electric guitars or hold hackathons or start a sci-fi reading group or screen films, there is space at the Gallery.
Science Gallery Bengaluru is a public space for knowledge. Such spaces began with Cabinets of Curiosities in the 16th century with collections from explorations across the world, and belonged to wealthy individuals. These gave way to natural historical collections-based public museums which were followed by the Exploratorium-inspired science centre model.
Tired of too many ads? go ad free now
Early museums were full of artistic descriptions of their collection.
Art described nature. Knowing something incredibly well was inseparable from visually representing it incredibly accurately – think of early botanical and anatomical drawings. Knowledge was enfolded into natural philosophy and moral philosophy and not yet siloed into disciplines as we take for granted today.
One remarkable thing about these early museums was that the object of study, the people studying them, and the public were in the same space.
That relationship between the public and the object or idea to know about, ways of knowing it, and why that matters is now lost. We believe in the value of reconstituting this relationship for today and we do that through our year-long research festivals.
Science Gallery Bengaluru is a space for open research. The Public Lab Complex at the Gallery draws on an inspiring story in modern Indian history. Chandrashekhar Venkata Raman is India's only Nobel Laureate in the natural sciences and nearly a century later, remains the only one who studied, worked and died in the country.
What is less known is that for the first 10 years of his professional life, he was an accountant with Indian Finance Service.
Interestingly, in the early morning and in the evenings, he conducted experiments in acoustics and later optics at Indian Association for Cultivation of Science in Calcutta, for a small bench fee, and that research eventually brought him the Nobel Prize.
We do not have that kind of space today. The nature of scientific research has changed: it has become highly specialised, expensive and is behind institutional walls.
We believe in the value of a space to nurture research ideas and a life of experimentation outside academia and industry but in collaboration with both.
Science Gallery Bengaluru disrupts learning silos. In India, we take disciplinary divergence to an extreme. Most of us do not have specialised conversations with people who are not professionally interfacing with us. It starts early. Engineers study with engineers, artists with artists, architects with architects, leading to an unfortunate narrowing of what students learn and consider is worth learning without being challenged on their assumptions.
No historian at the tender formative stage of his or her career is challenged by an engineer and no designer at that age has been challenged by a biologist in an academic setting.
This has consequences. The young have no opportunity to continuously defend their opinions and choices to someone who will be around for three to four years at the same dining table or at table tennis within the same institutional walls. This is changing in a few institutions but the thinking needs to take root more broadly.
We believe there is value in trying to disrupt this and we do so through our mentorship initiative.
Eighteen months after opening the doors to the Gallery, the three words that have become my Ursa Minor are 'Science, Culture and Experiment'. Science includes the human, the social and the natural sciences as equally important ways of knowing and of producing rigorous knowledge. Culture, because art – as understood by professionals – is just as distant from everyday life as scientific research is.
An expanded imagination of culture that envelopes creative expression across the arts and sciences is, perhaps, more hospitable.
Finally, Experiment. This institution is in itself an experiment. It is not a metaphor. The Public Lab Complex allows incubation of ideas and the conduct of collaborative experiments.
On 19 January 2024, we opened to the doors to our purpose-built premises with the exhibition Carbon and, most recently, SCI560 – both online and offline.
While the building was under construction, in October 2019, we started with public engagement programmes at other locations in the city, including at metro-stations with two physical exhibitions before the pandemic: Elements and Submerge. We were fully online during the pandemic and developed Phytopia, India's first fully online digital exhibition, followed by Contagion and Psyche.
All exhibition-seasons have successfully carried the vibe of a research festival.
Lectures, masterclasses, workshops, participatory programmes, a food festival and a film festival are integral to the exhibitions that change in August every year. We also develop online open courseware, activity handbooks and an exhibition-in-a-box every year that outlives and archives the exhibition for travel.
Why create a new model for a public space for knowledge? Why mix up the human, social, and natural sciences with engineering, art and design? What the coming together of the artist and scholar may allow for – minimally – is reflexive self-knowledge about making art, and about making knowledge. On a good day, it extends and expands both scientific research and the work of art.
In less than a month, we will launch a new exhibition, Calorie. Come over and hang out.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
24 minutes ago
- Mint
Indian contract drug makers timed their IPOs right. But is the business worth the premium?
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development. Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it. Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July. 'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier. About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines. The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO. The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted. Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs. Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value. Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53. Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%. Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26. Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore. Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas. 'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.' The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that. CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows. Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids). OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity. 'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response. Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries. Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues. 'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint. While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out. Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh. Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million. Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates. On the back of this, the growth outlook remains strong. "Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint. However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.


Hans India
24 minutes ago
- Hans India
AIIMS-led study shows two-drug combination therapy effective in controlling high BP
New Delhi: Using a single pill comprising two blood pressure medicines is a safe and highly effective way to treat hypertension among South Asians, particularly Indians, finds a study led by the All India Institute of Medical Sciences (AIIMS), New Delhi. The study, in partnership with the Centre for Chronic Disease Control (CCDC) and Imperial College London, UK, compared three widely used drug combinations: amlodipine plus perindopril, amlodipine plus indapamide, and perindopril plus indapamide. The first randomised trial to test three different two-drug combination pills among South Asians involved over 1,200 patients with uncontrolled hypertension across 32 hospitals in India. "All three combinations worked equally well in reducing blood pressure and were safe for patients,' revealed the study, published in the journal Nature Medicine. The findings showed that either of the two-drug combinations led to a significant drop in blood pressure after 6 months -- by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. 'Nearly 70 per cent of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care,' said Dr Ambuj Roy, Professor of Cardiology at AIIMS Delhi. 'This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients,' said Dr Dorairaj Prabhakaran, Executive Director of CCDC. High blood pressure (hypertension) is the leading risk factor for death worldwide and affects over 300 million people in India alone. Treating it early and effectively can prevent heart attacks, strokes, and kidney failure. Doctors often recommend starting with two medications in one pill to control blood pressure better and help patients stick to treatment. But until now, no large study had tested which combinations worked best for South Asians, who make up a quarter of the world's population. The results revealed that nearly 70 per cent of patients with any of the dual drug therapy reached the recommended blood pressure target of below 140/90 mmHg -- five times higher than India's current average control rate. Less than 3 per cent of patients reported side effects serious enough to stop treatment. 'These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country,' Prabhakaran said.


Time of India
2 hours ago
- Time of India
Uttarakhand@25: Surveyor general Makwana maps India's future on geospatial tech revolution
Surveyor general Makwana maps India's future on geospatial tech revolution In a special episode of Uttarakhand@25, a series by The Times of India celebrating 25 years of the state's journey, IAS officer Hitesh Kumar S Makwana, the surveyor general of India, sheds light on how geospatial technology is shaping India's present and future, with Uttarakhand playing a central role in that mission. Makwana, a 1995-batch IAS officer with an academic background in Civil Engineering, Economics, and Public Policy, brings over three decades of experience across urban governance, disaster management, border security, and housing. He currently heads the Survey of India, the country's national mapping agency. Dehradun's historic role in India's mapping legacy Makwana explained that while the Survey of India was initially established by the British in Kolkata in 1767, the headquarters eventually moved to Dehradun in 1951. The city's climate proved ideal for archiving sensitive mapping materials, and its proximity to institutions like IIT Roorkee provided skilled manpower. "Dehradun's role in the evolution of Indian cartography is immense. Even the original copies of the Constitution of India were printed in our Dehradun press,' he shared. The presence of more than 3,000 Survey of India employees in Dehradun during its peak also made the organisation one of the major employment generators in the region. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How Much Does a Bali Vacation Really Cost? Liseer Learn More Undo From traditional maps to real-time data Tracing the evolution of the Survey of India, Makwana described the shift from using manual tools like theodolites and chains to modern technologies such as remote sensing, LiDAR, and drones. Where earlier it took 70–80 years to complete a national map, now, with advanced geospatial tools, large-scale maps can be created in under a decade. These high-resolution maps — from a scale of 1:250,000 down to 1:2,000 — are transforming not just planning but also disaster management and urban development. Makwana highlighted the newly announced National Geospatial Mission, which aims to bring all of this data infrastructure together in a unified system, with Survey of India playing a leading role. Uttarakhand-specific projects: From Char Dham to land reforms When asked about Uttarakhand-specific work, Makwana emphasised several projects. The Survey of India had developed trekking maps of the Char Dham route as far back as the 1950s. In recent times, it has carried out aerial surveys of the Ganga basin for flood modelling under the National Hydrology Project and created comprehensive land-use maps for the National Mission for Clean Ganga. Additionally, under the Swamitva scheme, a drone-based survey was conducted in 7,000 villages of Uttarakhand to help residents receive digital land ownership records. This work is being extended to urban areas through the NAXA project, where four towns in the state have been selected for detailed geospatial surveys. Supporting urban planning and disaster preparedness Makwana explained how Survey of India data supports vital decision-making for roads, flood prevention, satellite launches, and more. 'Even ISRO needs to come to us to determine true north before launching a satellite,' he noted. The same data is now being used to predict landslides, monitor land subsidence, and address urban flooding by identifying vulnerable low-lying zones. This allows planners to design better drainage and locate green spaces strategically. Training the next generation To build future capacity, the Survey of India is training Uttarakhand's government staff, while collaborating with institutes like the Indian Institute of Remote Sensing in Dehradun. A certification programme for private citizens is also in the pipeline. Makwana stressed that the role of AI and Machine Learning in analysing massive geospatial datasets is set to expand — but the real challenge lies in training personnel to use these tools effectively. Message to the youth of Uttarakhand Speaking directly to Uttarakhand's youth, Makwana said, 'Sky is the limit. Geospatial technology is a booming sector. With Dehradun being the headquarters of Survey of India, local youth have a golden opportunity to lead the country in this space.' He closed with a call to action: 'Just as India has become a global leader in software, it is now time for us to become global leaders in geospatial technology — and Uttarakhand can be at the heart of that journey.'